Abstract Limited experience with the use of urethane in the treatment of leukemia indicates that this substance presents a considerable promise as a palliative agent in chronic myelogenous leukemia. It has no apparent value in the treatment of acute leukemia. Further extensive observation will be necessary to provide a true measure of the clinical usefulness of this preparation.